Wealth Effects LLC Sells 183 Shares of Danaher Co. (NYSE:DHR)

Wealth Effects LLC lessened its position in shares of Danaher Co. (NYSE:DHR) by 13.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,220 shares of the conglomerate’s stock after selling 183 shares during the period. Wealth Effects LLC’s holdings in Danaher were worth $280,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Stonegate Investment Group LLC grew its holdings in shares of Danaher by 2.2% during the fourth quarter. Stonegate Investment Group LLC now owns 225,199 shares of the conglomerate’s stock worth $51,694,000 after buying an additional 4,830 shares in the last quarter. VCI Wealth Management LLC boosted its position in Danaher by 5.1% during the 4th quarter. VCI Wealth Management LLC now owns 8,422 shares of the conglomerate’s stock worth $1,933,000 after acquiring an additional 406 shares during the last quarter. Town & Country Bank & Trust CO dba First Bankers Trust CO raised its holdings in shares of Danaher by 7.6% in the fourth quarter. Town & Country Bank & Trust CO dba First Bankers Trust CO now owns 10,550 shares of the conglomerate’s stock valued at $2,422,000 after purchasing an additional 743 shares during the last quarter. Buffington Mohr McNeal lifted its position in shares of Danaher by 0.3% in the fourth quarter. Buffington Mohr McNeal now owns 62,954 shares of the conglomerate’s stock worth $14,451,000 after purchasing an additional 169 shares in the last quarter. Finally, BankPlus Wealth Management LLC bought a new position in Danaher in the fourth quarter valued at $452,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Trading Up 1.9 %

Shares of DHR stock opened at $250.51 on Tuesday. Danaher Co. has a twelve month low of $225.42 and a twelve month high of $281.70. The stock’s fifty day simple moving average is $235.33 and its 200 day simple moving average is $253.62. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32. The firm has a market capitalization of $180.94 billion, a P/E ratio of 47.81, a P/E/G ratio of 4.43 and a beta of 0.83.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be paid a $0.27 dividend. This represents a $1.08 annualized dividend and a dividend yield of 0.43%. The ex-dividend date is Friday, December 27th. Danaher’s dividend payout ratio is currently 20.61%.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on DHR. Barclays decreased their price objective on Danaher from $285.00 to $275.00 and set an “equal weight” rating for the company in a report on Wednesday, October 23rd. Raymond James decreased their target price on shares of Danaher from $300.00 to $275.00 and set an “outperform” rating for the company in a research note on Tuesday, January 21st. KeyCorp raised their price objective on Danaher from $290.00 to $310.00 and gave the company an “overweight” rating in a research report on Wednesday, October 23rd. TD Cowen increased their price target on Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a research note on Wednesday, October 23rd. Finally, Stephens reiterated an “overweight” rating and set a $315.00 target price on shares of Danaher in a research report on Wednesday, October 23rd. Six analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $285.55.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.